Genfit : NASH : Elafibranor dans le trio de tête !
Les derniers mois ont été riches en données cliniques dans la NASH, cette nouvelle maladie métabolique du “foie grasâ€. La NASH pourrait être un marché très important d’ici quelques années (>15/20 Md$) et la concurrence commence à faire rage. Nous faisons le point sur les acteurs les plus avancés : Genfit ressort dans le trio de tête pour 4.5x moins cher que ses pairs ! Achat réitéré. OC relevé à 59 € (vs 46 €). - >2019, l’année de la NASH : 4 résultats d’études pivotales - ...Genfit is a biopharmaceutical company engaged in the discovery and development of drugs and biomarkers in therapeutic areas of high unmet need due to the lack of effective treatments or diagnostic tools and/or due to the increasing number of patients worldwide. Co. concentrates its research and development efforts to participate in the commercialization of treatment solutions and diagnostic tools to fight certain metabolic, inflammatory, autoimmune or fibrotic diseases affecting especially the liver (such as non-alcoholic steatohepatitis or "NASH").
Oddo Securities provides securities brokerage and research services. The company offers equity, economic, and derivatives research and credit analysis services. It focuses on insurance, automotive, building materials, pharmaceuticals, telecommunications, information technology, and agri-food industries.
Unfortunately, this report is not available for the investor type or country you selected.
Browse all ResearchPool reportsReport is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.